Because NLRP1 expression and IL-1β secretion are downstream mediators of TMZ-induced Notch activation (Figure 8), inhibiting NLRP1 and/or IL-1β could be used to regulate cancer aggressiveness and drug resistance, as we have shown in the current study. This evidence concerns the gene NLRP1 and cancer.